Eslami Says Israeli Missile Strike Targeted Radiopharmaceutical Plant

According to Khabaronline, an Iranian news agency, Mohammad Eslami, head of Iran’s Atomic Energy Organization, said on Thursday at the first conference of nuclear medicine, radio-oncology, and oncology specialists that Iran possesses more than 200 types of deuterated materials, which are used in medicine and other fields and can create significant synergies.

He added that there have been new developments in the field of plasma research, and Iran is currently conducting research and development alongside a few select countries. Eslami also noted that the country is actively expanding its work in laser technology.

Referring to the U.S. National Security Strategy, Eslami said, “The key goals for advancement outlined by the U.S. are artificial intelligence, nuclear technology, and quantum technologies. These objectives could apply to any country; they cannot be exclusive to one nation.”

“It is not acceptable for something to be forbidden for one country while allowed for others, yet the logic of power dictates that they explicitly state their interests are pursued not through international law and rights, but through force, he stated.”

Eslami emphasized that the public perception should understand that the real issue is the advancement of countries, not nuclear weapons.

He continued, “Many believed that Iranians must be doing something that others oppose, but the war and subsequent events showed these were merely excuses.”

Discussing a United Nations Security Council session on Iran, he stated, “The remarks from representatives of the three countries made it clear that their primary goal was to halt Iran’s progress; everything else was an excuse.”

He added, “The first target Israel struck with missiles during the conflict was the fuel plate production facility for the Tehran Research Reactor — the same facility that serves the public and symbolizes peaceful development. This shows that their actions are not about humanity or human rights; all of it is just rhetoric.”

The event was attended by specialists in nuclear medicine and oncology and focused on radiopharmaceuticals and new horizons in cancer diagnosis and treatment.

The conference covered topics including diagnostic and therapeutic applications of FAPI, prostate cancer, neuroendocrine tumors, and innovative cancer treatments using alpha-emitting radiopharmaceuticals such as Radium-223 and Actinium-225, as well as new therapies for non-melanoma skin cancers.